Phase I
The American Society of Gene & Cell Therapy (ASGCT) Annual Meeting kicked off Monday with multiple presentations highlighting the potential of new treatments for a myriad of diseases.
Achilles dosed the first patient in a Phase I/IIa advanced NSCLC trial, Logic Bio’s pediatric methylmalonic acidemia study is back up and running and another look at Roche’s TIGIT flop.
Genentech’s flop of its anti-TIGIT drug has cast a shadow of doubt over the numerous companies in the process of developing their own anti-TIGIT drugs.
Since the COVID-19 pandemic, there has been increased interest in developing a universal antiviral that would stop a pandemic in its tracks. Now some companies are in the testing phase for just that.
Marinus shared positive news in its financial report for the first quarter, led by updates from its Phase III trial on a drug for RSE and research efforts for rare diseases.
CRISPR reported that the overall response rate (ORR) was 71% with 29% of patients experiencing a complete response. The data will be presented at EHA 2022.
Cullinan and Taiho announced that Taiho was acquiring Cullinan Pearl and will co-develop and co-commercialize their non-small cell lung cancer drug.
Biopharma and life sciences organizations from across the globe provide updates on their businesses and pipelines.
Cortexyme has entered into a deal to acquire Novosteo. Once the deal is finalized, the companies will enter the rare disease space and operate under the name Quince Therapeutics.
In honor of World Lupus Day, BioSpace spoke with several companies making inroads in research and development for the treatment of the disease.
PRESS RELEASES